Table 2.
Genomic marker | Cancer type | Clinical use | Detection method | References |
---|---|---|---|---|
PD-L1 | Lung | Selection of patients for therapy | NGS-TMB determination | Cyriac and Gandhi, 201846 |
STX2 | Lung, colorectal | Exome sequencing, qRT-PCR | Lawrence et al., 2014;47 Wang et al., 201848 | |
ARHGAP35 | Lung, osteosarcoma | Risk associated to rs1052667 polymorphism detection | Exome sequencing, RNA sequencing, SNP Genotyping |
Kandoth et al., 201349; Lawrence et al., 201447; Zhao et al., 201450; Campbell et al., 201651 |
PIP | Breast | qRT-PCR | Gangadharan et al., 201851 | |
MSH2 | Hepatocellular carcinoma, lung | Risk associated to rs2303428 polymorphism detection |
SNP Genotyping | Zhu et al., 201852; Lo et al., 201153 |
ACYP2 | Breast | Risk associated to rs1682111 and rs10439478 polymorphisms detection | SNP Genotyping | Wu et al., 201854 |
NER genes ERCC1-5 RAD23B XPA XPC XPE |
Esophagus | Prognosis-associated to detection of rs3759497, rs3731054, rs2097215 and rs3916788 polymorphisms |
SNP Genotyping | Zhang et al.,201855 |
POLK | Prostate, melanoma, lung, large intestine | Risk associated to detection of 9 different polymorphisms | SNP Genotyping and site directed mutagenesis | Antczak et al., 201856 |
ERCC1 | Prostate | Cancer aggressiveness associated to detection of rs11615 polymorphism | SNP Genotyping | Henríquez-Hernández et al., 201457 |
ATM | Prostate | Cancer aggressiveness associated to detection of rs17503908 polymorphism; risk associated to specific mutation | SNP Genotyping, Genomic data analysis | Henríquez-Hernández et al., 201457
Marshall et al., 201858 |
BRCA1/2 | Prostate | Risk associated to specific mutation | SNP Genotyping | Marshall et al., 201858 |
VTCN1 | Breast, lung | Microarray analysis | Akiyama et al., 201659 | |
AKT1 PIK3CA PTEN TP53 |
Breast | Risk associated to specific mutation | NGS | Li et al., 201860 |
RUNX1 | Breast | Poor prognosis | Tissue microarray/IHC | Ferrari et al., 201461 |
miR-21 miR-210 |
Breast | Poor prognosis | Meta-analysis | Adhami et al., 201762 |
miR-15b-5p miR-16-5p miR-20a-5p |
Lung | Diagnostic | qRT-PCR/ Fluorescence quantum dots liquid bead array | Fan et al., 201563 |
miR-30b-5p miR-96-5p miR-182-5p miR-374b-5p miR-942-5p |
Breast | Diagnostic | Microarray/qRT-PCR | Zhang et al., 201764 |
SCGB2A2 | Prostate | Risk associated to differentially methylated detection from biological samples | Bisulfite-converted sample DNA assay | Sherlock et al., 201465 |
ZNF154 | Prostate | Prognosis | RNAseq/ NGS methylation detection | Zhang et al., 201866 |
ADAMTS1 BNC1 |
Pancreas | Early detection | Bisulfite-converted sample DNA assay | Eissa et al., 201967 |
CX43 | Lung | Poor prognosis | Tissue microarray/IHC | Aasen et al., 201968 |